Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background: Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) is a protein with altered glycosylation that reacts with lectin, and was recently identified as a useful non-invasive biomarker for the diagnosis of liver fibrosis in patients with hepatitis C virus infection.This study aimed to evaluate the diagnostic efficacy of WFA-M2BP for liver fibrosis in the context of hepatitis B virus (HBV). Methods: We enrolled 151 patients infected with HBV. Liver biopsy and elastography (Fibroscan) were performed during the initial visit. Fibrosis was graded according to the Knodell histologic activity index (F0–3). WFA-M2BP levels were determined with an automated immunoassay analyzer (M2BPGi, HISCL-5000, Sysmex, Japan). The diagnostic efficacy of WFA-M2BP was compared with those of various conventional or composite biomarkers, including enhanced liver fibrosis (ELF) score, Fibroscan, aspartate transaminase (AST)-toplatelet ratio index (APRI), and FIB-4, based on the area under the ROC curve (AUC) value. Results: The majority of patients were at fibrosis stages F1 and F2. The F2 and F3 AUC values for WFA-M2BP were similar to those for FIB-4, APRI, ELF, and Fibroscan, although the latter showed the best diagnostic efficacy. The diagnostic accuracy of all tested biomarkers for F2 and F3 was 60–70%. In multivariate analysis, WFA-M2BP, ELF, and platelet count significantly predicted stage ≥F2, whereas only platelet count significantly predicted F3. Conclusions: WFA-M2BP can support a diagnosis of liver fibrosis with similar diagnostic efficacy to other biomarkers, and predicted liver fibrosis stage ≥2 among patients with chronic hepatitis B.
Abstract
Background: Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) is a protein with altered glycosylation that reacts with lectin, and was recently identified as a useful non-invasive biomarker for the diagnosis of liver fibrosis in patients with hepatitis C virus infection.This study aimed to evaluate the diagnostic efficacy of WFA-M2BP for liver fibrosis in the context of hepatitis B virus (HBV). Methods: We enrolled 151 patients infected with HBV. Liver biopsy and elastography (Fibroscan) were performed during the initial visit. Fibrosis was graded according to the Knodell histologic activity index (F0–3). WFA-M2BP levels were determined with an automated immunoassay analyzer (M2BPGi, HISCL-5000, Sysmex, Japan). The diagnostic efficacy of WFA-M2BP was compared with those of various conventional or composite biomarkers, including enhanced liver fibrosis (ELF) score, Fibroscan, aspartate transaminase (AST)-toplatelet ratio index (APRI), and FIB-4, based on the area under the ROC curve (AUC) value. Results: The majority of patients were at fibrosis stages F1 and F2. The F2 and F3 AUC values for WFA-M2BP were similar to those for FIB-4, APRI, ELF, and Fibroscan, although the latter showed the best diagnostic efficacy. The diagnostic accuracy of all tested biomarkers for F2 and F3 was 60–70%. In multivariate analysis, WFA-M2BP, ELF, and platelet count significantly predicted stage ≥F2, whereas only platelet count significantly predicted F3. Conclusions: WFA-M2BP can support a diagnosis of liver fibrosis with similar diagnostic efficacy to other biomarkers, and predicted liver fibrosis stage ≥2 among patients with chronic hepatitis B.
참고문헌 (31)
- Ge PS, "Treatment of patients with Cirrhosis", N Engl J Med, 375, pp.767~777 (2016)[DOI]
- Rosenberg W, "Serum markers detect the presence of liver fibrosis: a cohort study", Gastroenterology, 127, pp.1704~1713 (2004)[DOI]
- Ellis E, "Clinical evidence for the regression of liver fibrosis", J Hepatol, 56, pp.1171~1180 (2012)[DOI]
- Ahmad W, "A brief review on molecule, genetic and imaging techniques for HCV fibrosis evaluation", Virol J, 8, pp.53~69 (2011)[DOI]
- Castera L, "Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?", Gut, 59, pp.861~866 (2010)[DOI]
- Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (Fibroscan)", Hepatology, 53, pp.885~894 (2011)[DOI]
- Theise N, "Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach", Mod Pathol, 20, pp.3~14 (2007)[DOI]
- Brunt EM, "Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond", Hepatology, 31, pp.241~246 (2000)[DOI]
- Parkes J, "Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease", Comp Hepatol, 11, pp.1~20 (2012)[DOI]
- Schuppan D, "Liver cirrhosis", Lancet, 371, pp.838~851 (2008)[DOI]
- Poynard T, "Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of liver fibrosis stages", Clin Chem, 53, pp.1615~1622 (2007)[DOI]
- Mallat A, "Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis", Am J Physiol Cell Physiol, 305, pp.C789~C799 (2013)[DOI]
- Nobili V, "Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease", Gastroenterology, 136, pp.160~167 (2009)[DOI]
- Guechot J, "Independent validation of the enhanced liver fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C", ClinChem Lab Med, 50, pp.693~699 (2012)
- Lichtinghagen R, "The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut off values", J Hepatol, 59, pp.236~242 (2013)[DOI]
- Yoo EJ, "Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea", Liver Int, 33, pp.706~713 (2013)[DOI]
- Kim BK, "Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B", PLos One, 7, pp.e41964~ (2012)[DOI]
- Kuno A, "A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment I patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)[DOI]
- Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients", Hepatology, 60, pp.1563~1570 (2014)[DOI]
- Narimatsu H, "Development of WFA-M2BP: a novel fibrosis serum glycol-biomarker for chronic hepatitis", cirrhosis diagnostics, 2015, pp.12, 683~693
- Ichikawa Y, "Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection", Hepatol Res, 47, pp.226~233 (2017)[DOI]
- Zou X, "Serum <TEX>$WFA^{+}$<", TEX>-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection, 2017, pp.37, 35~44
- Li Q, "The gamma-glutamyltranspeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B", Medicine, 95, pp.e3372~ (2016)[DOI]
- Nishikawa H, "A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation", Medicine, 95(35), pp.e4679~ (2016)[DOI]
- Boursier J, "An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis test: The Liver-FibroSTARD standards", J Hepatol, 62, pp.807~815 (2015)[DOI]
- CCLA, "Evaluation of precision performance of quantitative measurement methods; approved guideline, 3rd ed. NCCLS document EP5-A3", NCCLS, ~ (2014)
- Jang JW, "Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis", Hepatology, 61, pp.1809~1820 (2015)[DOI]
- Schweitzer A, "Estimation of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)[DOI]
- Hanafiah KM, "Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)[DOI]
- Petruzziello A, "Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes", World J Gastroenterol, 22, pp.7824~7840 (2016)[DOI]
- Kim YW, "Diagnostic usefulness of real-time elastography for liver fibrosis in chronic viral hepatitis B and C", Gastroenterol Res Pract, 2104, pp.210407~ (2014)